FindTrial
Sign In

Study to see whether 8mg or 12mg dexamethasone works better in reducing chemotherapy-related side effects

To compare the efficacy of intravenous dexamethasone 8mg with intravenous 12mg in Paclitaxel-Carboplatin chemotherapy associated adverse effects: A Randomized Open-Label Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/098654
Enrollment
100
Registered
2025-12-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Dexamethasone 8: Dexamethasone 8 mg will be administered intravenously as a single dose 30 minutes prior to the first Paclitaxel-Carboplatin chemotherapy cycle. The effect of this pre-m

Sponsors

Pharmacology Department Paraclinical Block Dr RPGMC Kangra at Tanda HP India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient receiving Paclitaxel-Carboplatin Willing adult patient giving written informed consent. Normal routine blood investigations.

Exclusion criteria

Exclusion criteria: Patient not willing to give written informed consent. Pregnant and Lactating females. Patient already on treatment with study drug.

Design outcomes

Primary

MeasureTime frame
Incidence and severity of Paclitaxel-induced hypersensitivity reactions graded by CTCAETimepoint: During paclitaxel infusion (from start to end) and up to 24 hours after infusion in the first chemotherapy cycle.—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactNidhi Mahlawat

Dr Rajendra Prasad Govt Medical College

atalsood7@gmail@gmail.com9418063191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026